Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion type Assertion NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_head.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion wasGeneratedBy ECO_0000203 NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_provenance.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion wasDerivedFrom gad-20130706 NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_provenance.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion SIO_000772 20683028 NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_provenance.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion evidence source_evidence_literature NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_provenance.
- NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_assertion description "[The distribution of NAT2 activity in the healthy control group was found to be correlated with that of healthy caucasians. Patients had slow acetylator phenotypes of NAT2, 1.8 times higher than controls but no statistical differences were found (p=0.07). In addition, the NAT2*5 alelle was more statistically correlated with breast cancer patients rather than the controls (p=0.02). Moreover, NAT2*5B was the most frequent haplotype of the NAT2*5 family (p=0.000). Breast cancer patients were detected to posses more CYP1B1*3 mutant alleles than the controls (p=0.043). The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP54024.RAbelkiZh9Yu50XcBsZhToG2Ice6cDEaE0qkCV_NIyndo130_provenance.